MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
Soligenix Long-Term Debt 2011-2026 | SNGX
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Soligenix
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 244 K | - | 1.01 M | 234 K | - | 9.95 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.95 M | 234 K | 2.86 M |
Quarterly Long-Term Debt Soligenix
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 274 K | 303 K | - | - | 11.5 K | 45.7 K | - | 1.01 M | 1.42 M | 2.09 M | 204 K | 234 K | 262 K | 290 K | - | - | - | - | 10 M | 10 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10 M | 11.5 K | 2.01 M |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
273 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
167 M | - | -24.86 % | $ 820 K |  USA |
 |
AbbVie
ABBV
|
64.5 B | $ 208.84 | -2.86 % | $ 369 B | USA |
 |
AbCellera Biologics
ABCL
|
137 M | $ 3.52 | 0.28 % | $ 1.05 B |  Canada |
 |
I-Mab
IMAB
|
68.2 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.42 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
173 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
1.83 M | - | -13.47 % | $ 169 M | France |
 |
Aeterna Zentaris
AEZS
|
31 K | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
4 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
9.12 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
529 K | - | - | $ 3.67 B | USA |
 |
Midatech Pharma plc
MTP
|
4.76 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
278 K | - | -1.52 % | $ 24.7 M | USA |
 |
Adverum Biotechnologies
ADVM
|
86 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
8.14 M | - | -9.65 % | $ 45.9 M | USA |
 |
AgeX Therapeutics
AGE
|
2.95 M | - | -10.17 % | $ 12.2 K | USA |
 |
Applied Molecular Transport
AMTI
|
49 K | - | - | $ 10.1 M | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
309 M | $ 74.21 | -2.3 % | $ 1.43 B | USA |
 |
Akouos
AKUS
|
28.3 M | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
175 M | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
210 K | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
3.38 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
69 K | - | 10.36 % | $ 9.8 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
20.8 M | $ 8.03 | 2.29 % | $ 220 M |  Israel |
 |
Adaptive Biotechnologies Corporation
ADPT
|
127 M | $ 14.81 | 2.63 % | $ 2.25 B | USA |
 |
Altimmune
ALT
|
34.3 M | $ 3.34 | 7.05 % | $ 294 M | USA |
 |
BioNTech SE
BNTX
|
231 M | $ 91.18 | 1.97 % | $ 27.2 B | Germany |
 |
Amgen
AMGN
|
50 B | $ 347.94 | -1.51 % | $ 187 B | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
52.3 M | $ 15.61 | 0.9 % | $ 2.1 B | Canada |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
22.1 M | - | -39.0 % | $ 4.57 M | USA |
 |
CureVac N.V.
CVAC
|
25.4 M | - | - | $ 867 M | Germany |
 |
BioCryst Pharmaceuticals
BCRX
|
315 M | $ 9.02 | -3.84 % | $ 1.86 B | USA |
 |
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
66.8 M | $ 1.41 | 2.17 % | $ 375 M | Britain |
 |
Atea Pharmaceuticals
AVIR
|
842 K | $ 5.76 | 1.95 % | $ 469 M | USA |
 |
BeiGene, Ltd.
BGNE
|
962 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AVROBIO
AVRO
|
188 K | - | 1083.1 % | $ 745 M | USA |
 |
Biogen
BIIB
|
6.29 B | $ 177.34 | -3.5 % | $ 26 B | USA |
 |
Axcella Health
AXLA
|
25.1 M | - | -16.42 % | $ 249 M | USA |
 |
Axon Enterprise
AXON
|
41.4 M | $ 412.81 | -2.54 % | $ 31.3 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.01 B | $ 318.85 | -3.01 % | $ 41.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.33 M | - | - | $ 7.46 M | Israel |
 |
Arbutus Biopharma Corporation
ABUS
|
806 K | $ 4.48 | -0.88 % | $ 858 M | Canada |
 |
bluebird bio
BLUE
|
37.7 M | - | - | $ 546 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
436 K | $ 55.5 | -3.04 % | $ 10.6 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
42.8 B | $ 59.6 | -2.45 % | $ 121 B | USA |